aware of letters being sent to compounders by Boehringer Ingelheim about their product Prascend (pergolide). The manufacturer cautions all pharmacists that any compounding of pergolide for veterinary use must only be done using their finished drug product and not the active pharmaceutical ingredient (API). If you’ve received that letter and want to know the specifics, contact us at iacpinfo@iacprx.org
To read more information on the IACP website, click here
No comments:
Post a Comment